Vascular KCNQ channels in humans

The sub-threshold brake that regulates vascular tone?

Bharath K. Mani, Kenneth L. Byron

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Contraction of arterial smooth muscle cells results in vasoconstriction, which in turn reduces blood flow and increases blood pressure. There has been a great deal of interest in understanding the ionic mechanisms that regulate smooth muscle contraction, in part because ion channels represent potential pharmacological targets for therapies directed towards cardiovascular diseases and other conditions. Potassium channels have been recognized for their roles in maintaining or stabilizing negative membrane voltages. Activation of potassium channels opposes opening of voltage-sensitive calcium channels which conduct calcium ions into the smooth muscle cells to stimulate contraction. KCNQ potassium channels were recently discovered in arterial smooth muscle cells from rats and mice. These channels have distinctive pharmacological and biophysical characteristics that have led them to be implicated as important regulators of membrane voltage and as novel pharmacological targets for modulation of vascular contractility. In this issue of British Journal of Pharmacology, Ng et al., extend the findings from rodent models to the human vasculature and establish that KCNQ channels also regulate constriction of human arteries. The findings have important implications for the use of pharmacological KCNQ channel modulators to treat human diseases.

Original languageEnglish (US)
Pages (from-to)38-41
Number of pages4
JournalBritish Journal of Pharmacology
Volume162
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Blood Vessels
Pharmacology
Smooth Muscle Myocytes
Potassium Channels
KCNQ Potassium Channels
Membranes
Calcium Channels
Muscle Contraction
Vasoconstriction
Ion Channels
Constriction
Smooth Muscle
Rodentia
Cardiovascular Diseases
Arteries
Ions
Blood Pressure
Calcium
Therapeutics

Keywords

  • human artery
  • KCNQ
  • potassium channel
  • vasoconstriction
  • vasodilation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Vascular KCNQ channels in humans : The sub-threshold brake that regulates vascular tone? / Mani, Bharath K.; Byron, Kenneth L.

In: British Journal of Pharmacology, Vol. 162, No. 1, 01.01.2011, p. 38-41.

Research output: Contribution to journalReview article

@article{500190be732e4aa4866a81b15473c274,
title = "Vascular KCNQ channels in humans: The sub-threshold brake that regulates vascular tone?",
abstract = "Contraction of arterial smooth muscle cells results in vasoconstriction, which in turn reduces blood flow and increases blood pressure. There has been a great deal of interest in understanding the ionic mechanisms that regulate smooth muscle contraction, in part because ion channels represent potential pharmacological targets for therapies directed towards cardiovascular diseases and other conditions. Potassium channels have been recognized for their roles in maintaining or stabilizing negative membrane voltages. Activation of potassium channels opposes opening of voltage-sensitive calcium channels which conduct calcium ions into the smooth muscle cells to stimulate contraction. KCNQ potassium channels were recently discovered in arterial smooth muscle cells from rats and mice. These channels have distinctive pharmacological and biophysical characteristics that have led them to be implicated as important regulators of membrane voltage and as novel pharmacological targets for modulation of vascular contractility. In this issue of British Journal of Pharmacology, Ng et al., extend the findings from rodent models to the human vasculature and establish that KCNQ channels also regulate constriction of human arteries. The findings have important implications for the use of pharmacological KCNQ channel modulators to treat human diseases.",
keywords = "human artery, KCNQ, potassium channel, vasoconstriction, vasodilation",
author = "Mani, {Bharath K.} and Byron, {Kenneth L.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1111/j.1476-5381.2010.01065.x",
language = "English (US)",
volume = "162",
pages = "38--41",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Vascular KCNQ channels in humans

T2 - The sub-threshold brake that regulates vascular tone?

AU - Mani, Bharath K.

AU - Byron, Kenneth L.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Contraction of arterial smooth muscle cells results in vasoconstriction, which in turn reduces blood flow and increases blood pressure. There has been a great deal of interest in understanding the ionic mechanisms that regulate smooth muscle contraction, in part because ion channels represent potential pharmacological targets for therapies directed towards cardiovascular diseases and other conditions. Potassium channels have been recognized for their roles in maintaining or stabilizing negative membrane voltages. Activation of potassium channels opposes opening of voltage-sensitive calcium channels which conduct calcium ions into the smooth muscle cells to stimulate contraction. KCNQ potassium channels were recently discovered in arterial smooth muscle cells from rats and mice. These channels have distinctive pharmacological and biophysical characteristics that have led them to be implicated as important regulators of membrane voltage and as novel pharmacological targets for modulation of vascular contractility. In this issue of British Journal of Pharmacology, Ng et al., extend the findings from rodent models to the human vasculature and establish that KCNQ channels also regulate constriction of human arteries. The findings have important implications for the use of pharmacological KCNQ channel modulators to treat human diseases.

AB - Contraction of arterial smooth muscle cells results in vasoconstriction, which in turn reduces blood flow and increases blood pressure. There has been a great deal of interest in understanding the ionic mechanisms that regulate smooth muscle contraction, in part because ion channels represent potential pharmacological targets for therapies directed towards cardiovascular diseases and other conditions. Potassium channels have been recognized for their roles in maintaining or stabilizing negative membrane voltages. Activation of potassium channels opposes opening of voltage-sensitive calcium channels which conduct calcium ions into the smooth muscle cells to stimulate contraction. KCNQ potassium channels were recently discovered in arterial smooth muscle cells from rats and mice. These channels have distinctive pharmacological and biophysical characteristics that have led them to be implicated as important regulators of membrane voltage and as novel pharmacological targets for modulation of vascular contractility. In this issue of British Journal of Pharmacology, Ng et al., extend the findings from rodent models to the human vasculature and establish that KCNQ channels also regulate constriction of human arteries. The findings have important implications for the use of pharmacological KCNQ channel modulators to treat human diseases.

KW - human artery

KW - KCNQ

KW - potassium channel

KW - vasoconstriction

KW - vasodilation

UR - http://www.scopus.com/inward/record.url?scp=78650126147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650126147&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2010.01065.x

DO - 10.1111/j.1476-5381.2010.01065.x

M3 - Review article

VL - 162

SP - 38

EP - 41

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -